TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04140123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601
Description: ZSP1601 tablets be taken orally for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601
Description: ZSP1601 tablets be taken orally for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601
Description: ZSP1601 tablets be taken orally for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZSP1601 Placebo
Description: Subjects will receive matching placebo of ZSP1601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 Placebo
Description: Subjects will receive matching placebo of ZSP1601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 Placebo
Description: Subjects will receive matching placebo of ZSP1601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601 Placebo
Description: Subjects will receive matching placebo of ZSP1601
Study: NCT01587768

Intervention type: DRUG
Intervention: Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009
Description: Antibiotics will be analysed overall, by class (tetracyclines, penicillins and betalactamics, cephalosporins, macrolides, aminoglycosides, quinolones and other antibiotics (sulphonamides \&amp; others combinations)) and individually. The antibiotics administered to patients include: cefuroxime axetil, cefuroxime sodium, ceftazidime sodium, amoxicillin, amoxicillin/ clavulanate, ampicillin, ampicillin/cloxacillin, flucloxacillin, ticarcillin, and ticarcillin/ clavulanate.

Intervention type: DRUG
Intervention: Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009
Description: Antibiotics will be analysed overall, by class (tetracyclines, penicillins and betalactamics, cephalosporins, macrolides, aminoglycosides, quinolones and other antibiotics (sulphonamides \&amp; others combinations)) and individually. The antibiotics administered to patients include: cefuroxime axetil, cefuroxime sodium, ceftazidime sodium, amoxicillin, amoxicillin/ clavulanate, ampicillin, ampicillin/cloxacillin, flucloxacillin, ticarcillin, and ticarcillin/ clavulanate.

Intervention type: DRUG
Intervention: Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009
Description: Antibiotics will be analysed overall, by class (tetracyclines, penicillins and betalactamics, cephalosporins, macrolides, aminoglycosides, quinolones and other antibiotics (sulphonamides \&amp; others combinations)) and individually. The antibiotics administered to patients include: cefuroxime axetil, cefuroxime sodium, ceftazidime sodium, amoxicillin, amoxicillin/ clavulanate, ampicillin, ampicillin/cloxacillin, flucloxacillin, ticarcillin, and ticarcillin/ clavulanate.
Study: NCT00401388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine is available in 50 mg tablets. Patients will take two perifosine 50 mg tablets orally once a day at bedtime with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine is available in 50 mg tablets. Patients will take two perifosine 50 mg tablets orally once a day at bedtime with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Perifosine is available in 50 mg tablets. Patients will take two perifosine 50 mg tablets orally once a day at bedtime with food.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: All patients should be instructed to take loperamide at the earliest signs of diarrhea and/or abdominal cramping after beginning perifosine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: All patients should be instructed to take loperamide at the earliest signs of diarrhea and/or abdominal cramping after beginning perifosine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: All patients should be instructed to take loperamide at the earliest signs of diarrhea and/or abdominal cramping after beginning perifosine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Patients with a known history of hyperuricemia and/or gout should receive prophylactic treatment with allopurinol 300 mg po daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Patients with a known history of hyperuricemia and/or gout should receive prophylactic treatment with allopurinol 300 mg po daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Patients with a known history of hyperuricemia and/or gout should receive prophylactic treatment with allopurinol 300 mg po daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiemetics
Description: Antiemetic prophylaxis will be administered at the treating investigator's discretion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiemetics
Description: Antiemetic prophylaxis will be administered at the treating investigator's discretion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiemetics
Description: Antiemetic prophylaxis will be administered at the treating investigator's discretion.
Study: NCT00950677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Byetta (exenatide)
Description: exenatide 5 mcg subcutaneously
Study: NCT03155646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
Study: NCT02481505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine HCl 1%
Description: Intrathecal Route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine HCl 1%
Description: Intrathecal Route
Study: NCT00950677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symlin (pramlintide)
Description: pramlintide 60 mcg subcutaneously
Study: NCT06224920

Intervention type: DIAGNOSTIC_TEST
Intervention: magnetic resonance imaging
Description: MRI data acquisition was performed on a 3 Tesla MRI scanner with parallel transmission and reception technology (Skyra Magnetom, Siemens Healthcare, Erlangen, Germany). Imaging is performed with a maximum gradient strength of 45mT/m and a maximum slew rate of 200 T/m/s and a 64-element head coil.

Intervention type: DIAGNOSTIC_TEST
Intervention: magnetic resonance imaging
Description: MRI data acquisition was performed on a 3 Tesla MRI scanner with parallel transmission and reception technology (Skyra Magnetom, Siemens Healthcare, Erlangen, Germany). Imaging is performed with a maximum gradient strength of 45mT/m and a maximum slew rate of 200 T/m/s and a 64-element head coil.
Study: NCT02481505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine HCl 1%
Description: Intrathecal Route
Study: NCT02525549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene and Benzoyl Peroxide Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene and Benzoyl Peroxide Gel (Reference)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Study: NCT00214422

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes.
Study: NCT06224920

Intervention type: DIAGNOSTIC_TEST
Intervention: magnetic resonance imaging
Description: MRI data acquisition was performed on a 3 Tesla MRI scanner with parallel transmission and reception technology (Skyra Magnetom, Siemens Healthcare, Erlangen, Germany). Imaging is performed with a maximum gradient strength of 45mT/m and a maximum slew rate of 200 T/m/s and a 64-element head coil.

Intervention type: OTHER
Intervention: electroencephalography
Description: A 20-channel resting EEG (Brain Products, Gilching, Germany) is recorded as part of routine clinical diagnostics in the Department of Psychiatry and Psychotherapy at the LMU to rule out focal neurophysiological pathologies. Within the scope of the present study, an extended examination will be carried out, which includes a 64-channel EEG, including a passive visual paradigm. After completion of the clinical evaluation, the neurophysiological changes in resting activity will be scientifically analyzed in comparison to the MRI and PET data.

Intervention type: OTHER
Intervention: electroencephalography
Description: A 20-channel resting EEG (Brain Products, Gilching, Germany) is recorded as part of routine clinical diagnostics in the Department of Psychiatry and Psychotherapy at the LMU to rule out focal neurophysiological pathologies. Within the scope of the present study, an extended examination will be carried out, which includes a 64-channel EEG, including a passive visual paradigm. After completion of the clinical evaluation, the neurophysiological changes in resting activity will be scientifically analyzed in comparison to the MRI and PET data.
Study: NCT03709927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZTI-01
Description: 6g IV fosfomycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZTI-01
Description: 6g IV fosfomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: oral moxifloxacin (Avelox 400 mg) + IV normal saline (Placebo)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: IV Placebo (0.9% Normal Saline)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo IV
Description: IV Placebo (0.9% Normal Saline)
Study: NCT03896295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M281
Description: M281 injection administered as intravenous infusion
Study: NCT03352531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK-105
Description: Anti-PD-1 monoclonal antibody; Subjects will receive AK105 by intravenous administration.
Study: NCT02039739

Intervention type: DEVICE
Intervention: Orsiro™ Drug Eluting Stent group
Study: NCT00214422

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes.
Study: NCT02424266

Intervention type: DEVICE
Intervention: None invasive imaging of the tear film (AdOM)
Description: White light tomography imaging

Intervention type: DEVICE
Intervention: None invasive imaging of the tear film (AdOM)
Description: White light tomography imaging
Study: NCT02126137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Study: NCT03047317

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MABp1
Description: Single dose of intravenous MABp1
Study: NCT02605928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injeq Bioimpedance Probe (BIP) Needle
Description: Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with synovial fluid.
Study: NCT03141840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABL01
Description: Experimental medical device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ABL01 lacking active component
Study: NCT05057650

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vegan diet
Description: Provide
Study: NCT01592578

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligation and Cyanoacrylate
Description: Patients will be treated with ligation for esophageal varices and cyanoacrylate for gastric varices when necessary.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ligation plus Sclerotherapy and Cyanoacrylate Group
Description: Patients will receive sclerotherapy after first ligation for esophageal varices and cyanoacrylate for gastric varices when necessary
Study: NCT00552669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral sirolimus
Description: Oral sirolimus given orally during 14 days plus bare metal stent implantation was compared with DES.Oral sirolimus was given as bolus of 10 mg started day before intervention followed by 3mg per day during 13 days after PCI. 180 mg of Diltiazem was added during oral administration of sirolimus .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug Eluting stent
Description: Any Drug eluting stent
Study: NCT06366477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration stimulation combined with task-oriented training
Description: Participants with chronic stroke underwent 24 sessions of vibration stimulation combined with task-oriented training over 12 weeks, in addition to regular therapy.
Study: NCT03922906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pure-Vu System
Description: Pure-Vu System is intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating and/or cleaning the colon and evacuating the irrigation fluid (saline water), feces and other bodily fluids and matter, e.g. blood.
Study: NCT01513434

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transtibial technique
Description: Femoral tunnel was made via tibial tunnel in anterior cruciate ligament reconstruction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transportal technique
Description: Femoral tunnel was made via anteromedial portal in anterior cruciate ligament reconstruction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior cruciate ligament reconstruction
Description: femoral and tibial tunneling graft fixation on the femoral side with endobutton and on the tibial side with post-tie and interference screw

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior cruciate ligament reconstruction
Description: femoral and tibial tunneling graft fixation on the femoral side with endobutton and on the tibial side with post-tie and interference screw
Study: NCT04517019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C
Description: Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitness tracker based activity training for Arm A and B. Booklet physical training, exercise and cancer and an introduction about physical activity during cancer therapy for Arm A, B, C
Description: Patients receive a fitness tracker, a booklet Physical training, exercise and cancer and an in-person briefing about physical activity during cancer therapy. With offered guidelines for the daily step counts patients should improve their physical activity during radiotherapy of breast cancer. A weekly feedback and a new goal for the next week will be provided until the individual patient reaches a daily activity of 6000 steps. The setting will be to maintain to this daily activity of 6000 steps during radiotherapy.
Study: NCT00660426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study: NCT02160210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrafine Endoscope
Description: Ultrafine endoscope reaching to the cecum within 15mins is thought to be successful.Water colonoscopy with standard colonoscope will be performed in unsuccessful subjects subsequently.
Study: NCT01894672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Study: NCT04127201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: en_línea
Description: This is an online adaptation of the LEARN program. A self-help weight control program developed by Kelly Brownell in 2004.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group therapy
Description: This is a traditional behavioral weight control program
Study: NCT00582894

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfex, Fludarabine, ALemtuzumab
Description: Busulfex 3.2 mg/kg/day for 2 days infused over 3 hours, Days -6 and Day-5 Fludarabine 30 mg/m2/day for 5 days on Day -6 to D-2 Alemtuzumab 10 mg/day IV on Days -5 to -1
Study: NCT03416231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib, at a dose of 250 mg daily,Treatment was continued until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel, at a dose of 75mg/m2 on days 1 and 22, repeat every 4 weeks for 4\~6 cycles.
Study: NCT04029857

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Supplement Drink
Description: Given standard of care nutritional supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplementation
Description: Given Impact Advanced Recovery PO or via feeding tube
Study: NCT02730260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nondirective smoking cessation coaching
Description: Quitline coach allows participant to set agenda for each call.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Directive smoking cessation coaching
Description: Quitline coach follows a pre-specified agenda for each call, and does not allow participant to deviate from the agenda.
Study: NCT03635931

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Concentrated Growth Factor
Description: surgical treatment with CGF for papilla regeneration
Study: NCT02771834

Intervention type: OTHER
Intervention: Biomechanical analysis

Intervention type: OTHER
Intervention: Biomechanical analysis

Intervention type: OTHER
Intervention: Kiphosis analysis
Study: NCT01876875

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy-restricted, n-3 polysaturated fatty acids-rich diet
Description: The active diet aimed to reduce body weight, to enhance the total intake of n-3 PUFA and to decrease the total intake of n-6 PUFAs. The diet plan was designed to supply an energy intake of 20 kcal/kg/day to maintain an ideal body weight, and followed the guidelines of the American Heart Association (AHA) 'Step-One' Diet: Carbohydrates (mainly complex carbohydrates) and protein constituted of 50-60% and 10-20% of total calories, respectively, and total fat did not exceed 30% of calories. Food values for energy and nutrients were taken from the tables of the Italian National Institute of Nutrition, Souci's Food Composition and Nutrition Tables and the European Institute of Oncology. For long-term and practical daily eating habits, it was important to easily incorporate and consume a variety of selected foods.
Study: NCT02771834

Intervention type: OTHER
Intervention: Vitamin D level
Study: NCT02305563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936564

Intervention type: DRUG
Group type: OTHER
Intervention: BMS-936564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Study: NCT00054132

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01290887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reslizumab
Description: Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 days), for approximately 24 months
Study: NCT00823641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
Study: NCT01876875

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual diet
Description: The patients of this group were randomized to continue their usual diet
Study: NCT01428947

Intervention type: PROCEDURE
Intervention: Arterial approach
Description: Randomization to right radial or femoral approach
Study: NCT02653703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical L-menthol 40%
Description: Naturally occurring local anaesthetic, counterirritant and TPRM8-agonist. CAS Number: 2216-51-5

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle, topical ethanol 96%
Description: Organic solvent CAS Number: 64-17-5
Study: NCT04399460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dairy-based commercially available food products
Description: Full-fat milk (3.25% milk, 250 mL), assortment of yogurts, and cheeses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dairy-based commercially available food products
Description: Full-fat milk (3.25% milk, 250 mL), assortment of yogurts, and cheeses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrictive Eating
Description: Dietitian will assist with 500 kcal/day reduction through limiting of macronutrients 45-65% energy from carbohydrates 20-35% energy from fat 10-35% energy from protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrictive Eating
Description: Dietitian will assist with 500 kcal/day reduction through limiting of macronutrients 45-65% energy from carbohydrates 20-35% energy from fat 10-35% energy from protein